



FtsZ and RnpA as Valid Targets while Developing Novel Antimicrobials

Guest Editor:

Dr. Valentina Straniero

Dipartimento di Scienze
Farmaceutiche, Università degli
Studi di Milano, Via Luigi
Mangiagalli, 25, 20133 Milan, Italy

Deadline for manuscript
submissions:

closed (31 January 2021)

Message from the Guest Editor

Dear Colleagues,

Antimicrobial resistance is a serious problem for public health. Investigating innovative antibacterial targets could be a favorable way to counteract this issue.

In the last decade two important proteins have started being considered and exploited, due to their crucial role in bacterial viability and to their established druggability: FtsZ and RnpA.

Both FtsZ and RnpA are widely conserved among the highest priority pathogens and have limited to null homology with eukaryotic proteins, hoping for broad-spectrum antimicrobials with low cytotoxicity on human cells.

This Issue would invite all researchers involved in fighting antimicrobial resistance by studying FtsZ and RnpA with different perspectives and positions. All manuscripts dealing with the design, synthesis, and the biological evaluation of novel antimicrobials targeting FtsZ and RnpA are welcome, as well as papers developing computational models, innovative assays, target-ligand characterization, crystallographic structures and biological mechanisms related to these two proteins.

Keywords: FtsZ inhibitors, RnpA inhibition, bacteriostatic effect, bacterial cell division process, mRNA turnover





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
X@antibioticsmdpi